Efficacy of Risperidone Orally Disintegrating Tablets Combined with Oxazepam in the Treatment of Schizophrenia

Objective. To explore the efficacy of risperidone orally disintegrating tablets combined with oxazepam in the treatment of schizophrenia. Methods. From May 2019 to May 2021, 60 patients with schizophrenia treated in our hospital were recruited and assigned into an observation group (risperidone oral...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022-08, Vol.2022, p.2344946-5
Main Authors: Fang, Liang, Xu, Ying, Tong, Xuefei, Wu, Xue, Zhou, Xiaomeng
Format: Article
Language:English
Subjects:
Activities of daily living
Alprazolam
Antipsychotics
Chlorpromazine
Disease
Mental disorders
Patients
Pharmaceuticals
Psychotropic drugs
Quality of life
Risperidone
Schizophrenia
Side effects
Substance abuse treatment
Tablets
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. To explore the efficacy of risperidone orally disintegrating tablets combined with oxazepam in the treatment of schizophrenia. Methods. From May 2019 to May 2021, 60 patients with schizophrenia treated in our hospital were recruited and assigned into an observation group (risperidone orally disintegrating tablets combined with oxazepam treatment) and a control group (alprazolam combined with chlorpromazine treatment) according to the random number table method. The positive and negative symptom score (PANSS), quality of life score (QOL-75), ability of daily living score (ADL), clinical efficacy, incidence of adverse reactions, and disease recurrence were compared between the two groups before and after treatment. Results. The PANSS scores were similar in the two groups before treatment (P>0.05). The two groups presented a declining trend in PANSS score after treatment, whereas a remarkable lower score in the observation group was observed (P0.05). Both groups witnessed improvements one month and three months after treatment, with considerable improvements being obtained in the observation group (all P0.05). At 1 month and 3 months after treatment, the ADL scores of the two groups were improved, with a higher score in the observation group (P0.05), while two and three months after treatment, they were lower than those of the control group (all P
ISSN:1741-427X
1741-4288
DOI:10.1155/2022/2344946